What question did this study set out to answer?

Assess weight and safety outcomes in patients with obesity treated with GLP-1 medications via telehealth.

December 10, 2025Obesity

Real‐World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort shows semaglutide achieves significant weight loss in obesity via telehealth, indicating safety.

Assess weight and safety outcomes in patients with obesity treated with GLP-1 medications via telehealth.
Analyzed deidentified EHR data for 4500 patients treated with semaglutide via telehealth.
Examined weight outcomes within ±14 days after week 68 of treatment.
Evaluated predictors of weight loss outcomes across the cohort.
Mean body weight reduction was −16.6% with a standard deviation of 7.5%.
Female sex significantly increased odds of weight loss at ≥ 5% (OR 4.26), ≥ 10% (OR 5.90), and ≥ 20% (OR 2.51).
Common adverse events included nausea/vomiting (37.3%) and constipation (15.6%); no new safety signals were identified.

Tchang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark